English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, December 11, 2019
エーザイ、人事異動ならびに組織改編を発表
Tuesday, December 10, 2019
エーザイ、筑波研究所の大規模改修工事を開始
Commencement of Major Renovation of Tsukuba Research Laboratories as Eisai Global Drug Discovery Center Aiming for Connecting Human and Human, and Data, and the World
Monday, December 9, 2019
シスメックスとエーザイ、血液による簡便なアルツハイマー病診断法の創出に向けた学術報告を発表
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer's Disease Using Blood
Eisai Satisfies All-Case Surveillance Condition for Approval of Anti-Cancer Agent Lenvima in Treatment of Thyroid Cancer
Friday, December 6, 2019
エーザイ、「レンビマ」の甲状腺がんに係る適応の承認条件(全例調査)解除について
Thursday, December 5, 2019
エーザイ、第42回サンアントニオ乳がんシンポジウムにおいてエリブリン(ハラヴェン(R))に関する演題を発表
Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium
Monday, December 2, 2019
エーザイ、「レンビマ」(レンバチニブ)が中国での分化型甲状腺がんに係る適応追加申請を受理

Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575